Profile

Change your cover photo
Change your cover photo
This user account status is Approved

This user has not added any information to their profile yet.

Rosa
Abrantes-Metz





Organization Profile

Positions:

  • Principal, Global Economics Group
  • Adjunct Associate Professor, NYU Stern School of Business
    New York, New York

Experience & Areas of Interest:

Dr. Rosa M. Abrantes-Metz's experience includes work in consulting and banking, as well as in government. Her main areas of specialization are econometrics, financial economics, monetary economics, and applied industrial organization. Dr. Abrantes-Metz is an Associate Adjunct Professor at Leonard N. Stern School of Business, New York University, where she teaches industrial economics. She has taught econometrics at the department of economics at the University of Chicago, and various other fields of economics at Universidade Catolica Portuguesa, in Lisbon, Portugal.

Since working as a staff economist at the Federal Trade Commission, Dr. Abrantes-Metz continued serving as a consultant for special projects with the Commission's Bureau of Economics. She is the author of several articles on econometric methods, conspiracies and manipulations, gasoline, pharmaceuticals and healthcare, event studies, and has published in many peer-reviewed journals. Dr. Abrantes-Metz is a co-drafter of the chapter on the role of the economic expert in proving conspiracy cases under federal antitrust laws, a recent volume by the American Bar Association, and a contributor to other books on antitrust and international arbitration with a focus on event studies.

Dr. Abrantes-Metz has developed numerous screens for conspiracies and manipulations, and is a pioneer in the field, contributing to the increased adoption of these empirical methods. She has flagged potential anti-competitive behavior preceding large-scale worldwide investigations, such as the alleged Libor conspiracy and manipulation (LIBOR Manipulation? (2008) and Tracking the Libor Rate (2010)). At the time the first investigations on Libor surfaced, Dr. Abrantes-Metz's work was covered by the Wall Street Journal and the Financial Times. Her screens are used by competition authorities worldwide and also by defendants.

In pharmaceuticals, she has co-developed a model to estimate the likelihood of drugs failing and succeeding each of the clinical stages of the Food and Drug Administration, and their expected durations in each of these phases. This model has become one of the two most used by industry analysts to value pharmaceutical and biotechnology pipelines. Her research on pharmaceuticals and conspiracies has been discussed in books on how to value pharmaceutical and biotechnology companies, and on publications pertaining to healthcare, intellectual property and cartels. She has presented her work to competition authorities all over the world. Dr. Abrantes-Metz has provided testimony related to alleged bid-rigging and price-fixing, and in international arbitration on the valuation of expropriated assets.

Education:

  • 2002, University of Chicago, PhD
  • 1997, University of Chicago, MA
  • 1996, Universitat Pompeu Fabra, MA
  • Licenciatura in Economics from Universidade Catolica Portuguesa




In addition to writing the papers listed below, Dr. Abrantes-Metz has taught classes on econometrics for the CPI Learning Center. You can view these here.

POST DATE
Antitrust Compliance 2.0: The Use of Structural Analysis and Empirical Screens to Detect Collusion and Corruption in Bidding Procurement Processes
2015-06-29
Recent Successes of Screens for Conspiracies and Manipulations: Why Are There Still Skeptics?”
2014-10-28
Health Care Benefits vs. Costs: Are We Making the Right Choices?
2014-09-26
Did Credit Rating Agencies Cause the European Sovereign Debt Crisis?
2014-01-28
Is There Misdiagnosis and Mistreatment in the Market for Credit Ratings?
2013-12-17
Is There Misdiagnosis and Mistreatment in the Market for Credit Ratings?
2013-11-25
Seven Principles for Reforming Financial Benchmarks
2013-03-04
Libor, Screening & Reform
2013-01-08
Will Wheatley’s Recommendations Fix the LIBOR?
2012-12-27
How to Fix the Libor
2012-12-27
Lessons from LIBOR for Detection and Deterrence of Cartel Wrongdoing
2012-11-27
Will The Wheatley Recommendations Fix LIBOR?
2012-11-27
Why a Reduction in Health Care Costs Per Se May be a Misleading Policy Objective
2012-07-27
CPI Cartel Column - Note from the Editor
2012-07-20
Why and How Should the Libor Be Reformed?
2012-07-16
Antitrust and Regulation: Credit Rating Agencies
2012-06-29
Screens for Conspiracies and Their Multiple Applications (reprint)
2012-06-18
Interview: Update on "Screens for Conspiracies and Their Multiple Applications"
2012-06-16
How Far Can Screens Go in Distinguishing Explicit from Tacit Collusion? New Evidence on the Libor Setting
2012-03-13
Why and How to Use Empirical Screens in Antitrust Compliance
2012-02-14

    1 2